Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease.
Qing Ya WangYuan LiZe Yin LiangYue YinWei LiuQian WangYu Jun DongYu Hua SunWei Lin XuHan Yun RenPublished in: Cancer management and research (2019)
Inclusion of Decitabine in the conditioning regimen for allo-HSCT in intermediate- and high-risk patients may lower the incidence of aGVHD and respiratory infections, and contribute to longer median relapse time.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- risk factors
- acute lymphoblastic leukemia
- ejection fraction
- newly diagnosed
- chronic kidney disease
- liver failure
- peritoneal dialysis
- respiratory failure
- hepatitis b virus
- drug induced
- free survival
- patient reported
- extracorporeal membrane oxygenation
- hematopoietic stem cell